证券代码：000766 证券简称：通化金马 公告编号：2025-33 通化金马药业集团股份有限公司 关于公司为全资子公司提供担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 截至目前，被担保公司哈尔滨圣泰生物制药有限公司资产负债率超过 70%。 本次公司对哈尔滨圣泰生物制药有限公司的担保金额超过公司 2024 年度经审计 净资产的 50%。本次担保提供后，公司及控股子公司实际对外担保余额将超过公 司 2024 年度经审计净资产的 100%，全部公司为对合并报表范围内全资子公司的 担保和合并报表范围内子公司对子公司的担保。请投资者充分关注担保风险。 一、担保情况概述 （二）董事会审议情况 2025 年 8 月 28 日，公司第十一届董事会 2025 年第七次临时会议以 9 票同 意、0 票反对、0 票弃权审议通过了《关于公司为全资子公司哈尔滨圣泰生物制 药有限公司向银行申请贷款提供担保的议案》。根据《深圳证券交易所股票上市 规则》6.1.10 条规定，本议案须提交股东会审议。 二、被担保人基本情况 1、被担保人简介 名称：哈尔滨圣泰生物制药 ...

通化金马药业集团股份有限公司 关于召开2025年第三次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 通化金马药业集团股份有限公司(以下简称"公司")第十一届董事会2025 年第七次临时会议审议通过了《关于召开2025年第三次临时股东会的议案》，决 定于2025年9月15日召开公司2025年第三次临时股东会，审议董事会提交的相关 议案，现将本次会议的有关事项通知如下： 一、召开会议的基本情况 1．股东会届次：2025年第三次临时股东会。 证券代码：000766 证券简称：通化金马 公告编号：2025-34 2．股东会的召集人：公司董事会。 3．会议召开的合法、合规性：经公司第十一届董事会2025年第七次临时会 议审议通过，决定召开公司2025年第三次临时股东会，本次股东会会议召开符合 有关法律、行政法规、部门规章、规范性文件、深圳证券交易所业务规则和《公 司章程》的规定。 4．会议召开的日期、时间： 现场会议时间：2025年9月15日下午14:30 网络投票时间：2025年9月15日，其中，通过深圳证券交易所交易系统进行 网络投票的具体时间为 ...

证券代码：000766 证券简称：通化金马 公告编号：2025-32 通化金马药业集团股份有限公司 第十一届董事会 2025 年第七次临时会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1.通化金马药业集团股份有限公司第十一届董事会2025年第七次临时会议通知 于2025年8月27日以微信和电子邮件形式送达全体董事。 2.2025 年 8 月 28 日上午 9 时 30 分以现场和通讯方式召开。 3.会议应到董事9人，实到董事9人。 4.会议由董事长张玉富先生主持，部分高管人员列席了本次会议。 5.本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文件和 公司章程的规定。 1、审议并通过关于公司全资子公司哈尔滨圣泰生物制药有限公司向银行申请 贷款的议案 为满足全资子公司哈尔滨圣泰生物制药有限公司（以下简称"圣泰生物"）生产 经营和发展的需要，圣泰生物拟向营口银行股份有限公司（以下简称"营口银行"） 申请最高额不超过 15.70 亿元的信用贷款，贷款期限三年，在该额度期限内可循环 滚动使用。 董事会授权经营层全权办 ...

Group 1 - The core viewpoint of the article highlights the growth in the number of enterprises in the chemical raw materials and chemical products manufacturing industry, which increased by 1,021 to a total of 26,860 enterprises in the first half of 2025, representing a year-on-year growth of 3.95% [1] - The proportion of chemical raw materials and chemical products manufacturing enterprises in the total industrial enterprises is 5.16% [1] - The report referenced is the "2025-2031 China Basic Chemical Raw Materials Industry Market Supply and Demand Situation and Investment Prospects Analysis Report" published by Zhiyan Consulting [1] Group 2 - The data indicates that the threshold for scale industrial enterprises has been raised from an annual main business income of 5 million yuan to 20 million yuan since 2011 [1] - Zhiyan Consulting is recognized as a leading industry consulting agency in China, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1] - The consulting firm emphasizes its commitment to delivering quality services and market insights to empower investment decisions [1]

Group 1 - The core point of the article is that Tonghua Jinma (000766) confirmed the normal operation and good credit status of its wholly-owned subsidiary, Shengtai Biological, in response to investor inquiries on August 26 [1] Group 2 - The company reassured investors about the operational stability and financial health of its subsidiary, indicating a positive outlook for its business activities [1]

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Core Insights - The chemical pharmaceutical sector experienced a rise of 0.48% on August 22, with Duori Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3825.76, up 1.45%, while the Shenzhen Component Index closed at 12166.06, up 2.07% [1] Stock Performance - Duori Pharmaceutical (301075) closed at 45.48, with an increase of 8.54% and a trading volume of 98,000 shares, amounting to a transaction value of 426 million [1] - Maiwei Biological (688062) saw a closing price of 39.22, up 7.10%, with a trading volume of 194,300 shares, totaling 749 million [1] - Lifan Pharmaceutical (003020) closed at 38.48, increasing by 6.68%, with a trading volume of 153,200 shares, resulting in a transaction value of 584 million [1] - Other notable performers included Tonghua Jinma (000766) with a 6.03% increase and Qianhong Pharmaceutical (002550) with a 5.52% increase [1] Fund Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 1.428 billion from institutional investors, while retail investors contributed a net inflow of 1.492 billion [2] - The table of fund flows indicates that Qianhong Pharmaceutical (002550) had a net inflow of 157 million from institutional investors, while it experienced a net outflow of 44.058 million from speculative funds [3] - Other companies like Lijun Group (000513) and Xianju Pharmaceutical (002332) also showed varying net inflows and outflows from different investor categories [3]

Core Viewpoint - Tonghua Jinma (000766) reported a slight increase in total revenue and a significant rise in net profit for the first half of 2025, indicating improved profitability despite rising short-term debt pressure [1][2]. Financial Performance - Total revenue for the first half of 2025 reached 650 million yuan, a year-on-year increase of 0.12% [1]. - Net profit attributable to shareholders was 16.804 million yuan, up 34.77% year-on-year [1]. - In Q2 2025, total revenue was 351 million yuan, a decrease of 0.82% compared to the same quarter last year, while net profit rose by 59.08% to 5.2212 million yuan [1]. - Gross margin was 73.32%, down 2.54% year-on-year, while net margin improved by 36.25% to 2.59% [1]. - Total operating expenses were 427 million yuan, accounting for 65.72% of revenue, a decrease of 5.21% year-on-year [1]. Cash Flow and Debt Situation - Operating cash flow per share increased by 104.8% to 0.08 yuan, indicating improved cash generation [1][2]. - The company’s liquidity ratio was reported at 0.58, indicating rising short-term debt pressure [1][3]. - The ratio of interest-bearing liabilities to total assets reached 40.85%, highlighting a significant debt burden [3]. Investment Metrics - The company's return on invested capital (ROIC) was 3.42%, indicating weak capital returns [2]. - The net profit margin for the previous year was 4.23%, suggesting low added value in products or services [2]. - Historical data shows a median ROIC of 2.84% over the past decade, with six years of losses since the company went public [2]. Fund Holdings - Major funds holding Tonghua Jinma include Yinhua CSI Innovation Drug Industry ETF and Southern CSI 1000 ETF, indicating growing institutional interest [3].

Core Insights - The company reported a total revenue of 650 million yuan and a net profit attributable to shareholders of 16.80 million yuan for the first half of 2025 [2] - The operating cash flow showed a net inflow of 78.05 million yuan [2] Financial Performance - The latest asset-liability ratio stands at 49.91%, which is an increase of 0.02 percentage points from the previous quarter and an increase of 0.58 percentage points compared to the same period last year [4] - The gross profit margin is reported at 73.32%, reflecting a decrease of 1.91 percentage points year-on-year [4] - The return on equity (ROE) is recorded at 0.74% [4] - The diluted earnings per share (EPS) is 0.02 yuan [5] Operational Efficiency - The total asset turnover ratio is 0.14 times, while the inventory turnover ratio is 0.46 times [6] Shareholder Structure - The number of shareholders is approximately 39,500, with the top ten shareholders holding a total of 392 million shares, accounting for 40.59% of the total share capital [6] - The largest shareholder, Yu Lanjun, holds 19.66% of the shares [6]

Core Insights - Tonghua Jinma (000766.SZ) reported a total operating revenue of 650 million yuan for the first half of 2025, reflecting an increase of 802,100 yuan or 0.12% year-on-year [1] - The net profit attributable to shareholders reached 16.804 million yuan, up by 4.3357 million yuan or 34.77% compared to the same period last year, marking three consecutive years of growth [1] - The net cash inflow from operating activities was 78.0476 million yuan, an increase of 39.9391 million yuan or 104.80% year-on-year [1] Financial Metrics - The latest debt-to-asset ratio stands at 49.91% [3] - The gross profit margin is reported at 73.32%, an increase of 1.71 percentage points from the previous quarter [3] - The return on equity (ROE) is 0.74%, up by 0.20 percentage points compared to the same period last year [3] - The diluted earnings per share remained stable compared to the same period last year, with a year-on-year increase of 34.88% [3] - The total asset turnover ratio is 0.14 times, unchanged from the previous year but up by 1.19% year-on-year [3] - The inventory turnover ratio is 0.46 times, an increase of 0.04 times or 9.23% year-on-year [3] Shareholder Structure - The number of shareholders is approximately 39,500, with the top ten shareholders holding a total of 392 million shares, accounting for 40.59% of the total share capital [3] - The largest shareholder is Yu Lanjun, holding 19.61% of the shares [3]